DOCSLIB.ORG

Sulfatide Analysis by Mass Spectrometry for Screening Of

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Sulfatide Analysis by Mass Spectrometry for Screening Of Papers in Press. Published November 19, 2015 as doi:10.1373/clinchem.2015.245159 The latest version is at http://hwmaint.clinchem.org/cgi/doi/10.1373/clinchem.2015.245159 Clinical Chemistry 62:1 Automation and Analytical Techniques 000–000 (2016) Sulfatide Analysis by Mass Spectrometry for Screening of Metachromatic Leukodystrophy in Dried Blood and Urine Samples Zdenek Spacil,1* Arun Babu Kumar,1 Hsuan-Chieh Liao,1 Christiane Auray-Blais,2 Samantha Stark,3 Teryn R. Suhr,4 C. Ronald Scott,5 Frantisek Turecek,1 and Michael H. Gelb1,6* BACKGROUND: Metachromatic leukodystrophy (MLD) for newborn screening of MLD and sets the stage for a is an autosomal recessive disorder caused by deficiency larger-scale newborn screening pilot study. in arylsulfatase A activity, leading to accumulation of © 2015 American Association for Clinical Chemistry sulfatide substrates. Diagnostic and monitoring proce- dures include demonstration of reduced arylsulfatase Aactivityinperipheralbloodleukocytesordetection Metachromatic leukodystrophy (MLD),7 caused by de- of sulfatides in urine. However, the development of a ficiency of arylsulfatase A (EC 3.1.6.8), is a severe clinical screening test is challenging because of instability of condition categorized into infantile, late infantile, juve- the enzyme in dried blood spots (DBS), the wide- nile, and adult subtypes according to age of onset. New- spread occurrence of pseudodeficiency alleles, and the born screening (NBS) of MLD by direct measurement of lack of available urine samples from newborn screen- arylsulfatase A activity or protein abundance is not likely ing programs. to be feasible because of a severe pseudodeficiency prob- lem (1) and relative instability of the enzyme in dried METHODS: We measured individual sulfatide profiles in blood spots (DBS) (2). Sulfatides, the natural substrates DBS and dried urine spots (DUS) from MLD patients for arylsulfatase A, have been shown to be highly in- with LC-MS/MS to identify markers with the discrimi- creased in urine from MLD patients compared with natory power to differentiate affected individuals from healthy individuals (3–7). However, NBS programs typ- controls. We also developed a method for converting all ically use DBS, and dried urine samples (DUS) are usu- sulfatide molecular species into a single species, allowing ally not available. Recent studies have shown that sulfati- quantification in positive-ion mode upon derivatization. des are increased in DBS from MLD patients (8, 9), but the discriminatory power of sulfatide concentrations in RESULTS: In DBS from MLD patients, we found up to DBS between MLD patients and controls is less pro- 23.2-fold and 5.1-fold differences in total sulfatide con- nounced than in DUS, raising questions about the po- centrations for early- and late-onset MLD, respectively, tential for NBS. The interest in screening for MLD is compared with controls and pseudodeficiencies. Corre- timely owing to new treatment options being investi- sponding DUS revealed up to 164-fold and 78-fold dif- gated in the clinic (10). ferences for early- and late-onset MLD patient samples Sulfatides occur as an ensemble of molecular species compared with controls. The use of sulfatides converted caused by variation in the structure of the fatty acyl chain to a single species simplified the analysis and increased attached to the sphingosine amino group (3). In the detection sensitivity in positive-ion mode, providing a study reported here, we developed and optimized new second option for sulfatide analysis. tandem mass spectrometry (MS/MS) methods to detect sulfatides in DBS and DUS as disease markers of MLD. CONCLUSIONS: This study of sulfatides in DBS and DUS The first method covers the entire panel of sulfatide mo- suggests the feasibility of the mass spectrometry method lecular species with ultra-high performance liquid chro- 1 Department of Chemistry, 5 Department of Pediatrics, and 6 Department of Biochemis- Received June 16, 2015; accepted November 5, 2015. try, University of Washington, Seattle, WA; 2 Clinical Research Center, Centre Hospitalier Previously published online at DOI: 10.1373/clinchem.2015.245159 Universitaire de Sherbrooke, and Universite´de Sherbrooke, Sherbrooke, Quebec, Can- © 2015 American Association for Clinical Chemistry ada; 3 National Referral Laboratory, Genetics and Molecular Pathology, South Australia 7 Nonstandard abbreviations: MLD, metachromatic leukodystrophy; NBS, newborn Pathology, Women’s and Children’s Hospital, Adelaide, Australia; 4 MLD Foundation, screening; DBS, dried blood spots; DUS, dried urine samples; MS/MS, tandem mass West Linn, OR. spectrometry;UHPLC,ultra-highperformanceliquidchromatography;SCDase,sphingo- * Address correspondence to these authors at: Department of Chemistry, Campus Box lipid ceramide N-deacylase; SM, sphingomyelin. 351700, University of Washington, Seattle, WA 98195. Fax 206-685-8665; e-mail [email protected] or [email protected]. 1 Copyright (C) 2015 by The American Association for Clinical Chemistry matography (UHPLC) and MS/MS in negative ion 10-mm DUS punch, except with 50 ␮L water and 500 mode without the need to derivatize the analyte. The ␮L methanol. second method involves the enzymatic conversion of all sulfatide molecular species into a single species (lysosul- ENZYMATIC CONVERSION AND DERIVATIZATION OF fatide), after hydrolysis of fatty acid. Lysosulfatide is then SULFATIDES converted into a derivative that can be readily detected by DBS were incubated in a deep (1-mL) 96-well plate for UHPLC-MS/MS in positive-ion mode. We compared 16 h (37 °C with orbital shaking) in 30 ␮Lof50 these methods by analyzing DBS and DUS from Յ100 mmol/L sodium acetate buffer, pH 6.0, containing control samples and 14 MLD patients with various ages 0.8% taurodeoxycholate and 2 mU sphingolipid cer- of onset of clinical symptoms. amide N-deacylase (SCDase) (cat. no. S2563, Sigma Aldrich). The reaction was quenched with 300 ␮L Materials and Methods methanol, and 200 ␮Lwastransferredtoashallow (350 ␮L) 96-well plate. For direct lysosulfatide analy- All studies with human samples were carried out with sis, samples were transferred and subjected to LC- institutional review board approval at the University MS/MS analysis. For the analysis of lysosulfatide de- of Washington. DUS and DBS from MLD patients rivative, the methanol was evaporated under a stream were collected and provided by the MLD Foundation of nitrogen, and 50 ␮Lof5mmol/Lsuccinylester (http://www.mldfoundation.org/). We obtained DBS reagent (see Supplemental Material, which accompa- from MLD pseudodeficient patients from the Na- nies the online version of this article at http://www. tional Referral Laboratory, Genetics and Molecular clinchem.org/content/vol62/issue1) in ethanol was Pathology, South Australia Pathology, Women’s and added to each well. The plate was sealed with a silicone Children’s Hospital, Adelaide, Australia. Anonymized mat and incubated for2hat37°Cwith orbital shak- control DUS and DBS from healthy newborns were ing. Methanol (150 ␮L) was added to each well, and obtained from the Centre Hospitalier Universitaire de the sample was subjected to LC-MS/MS analysis. Sherbrooke before being discarded. DBS from MLD patients were collected by puncturing the fingertip UHPLC-MS/MS ANALYSIS with a lancet and letting the blood drip onto Whatman For UHPLC separation, we used an Acquity system 903 filter paper, which was air-dried for approximately equipped with an analytical column, HSS T3 C18 (50 ϫ 2handthenmailedatambienttemperatureoverafew 2.1 mm, 1.8 ␮m), and a guard column, VanGuard HSS days to the University of Washington. DUS from T3 (5 ϫ 2.1 mm, 1.8 ␮m), all from Waters Corp. The MLD patients were collected on Whatmann-GE 903 UHPLC solvents were water/acetonitrile (50:50) with paper disks (70 mm), which were allowed to air-dry for 0.1% formic acid (solvent A) and 2-propanol/acetonitrile approximately2hatroom temperature, then placed in (80:20) with 0.1% formic acid (solvent B). The elution azip-lockplasticbagforshipmentatambienttemper- solvents were prepared from LC-MS Optima grade ace- ature. After receipt, DBS and DUS were stored at tonitrile Ն99.9% (cat. no. 34967, Fisher), water, Ϫ20 °C in a closed jar with desiccant. DBS were man- 2-propanol, methanol Ն99.9% (cat. no. 34860), and ually punched with a 3-mm-diameter perforator, and a formic acid approximately 98% (cat. no. 06440). The single 3-mm punch was used for analysis in microtiter gradient elution program started with 50% solvent B, plate format. DUS were punched with a 3- or 10-mm- 0–1 min to 95% solvent B (linear), 1–1.5 min to 100% diameter perforator, and a single 10-mm punch or two solvent B (linear), 1.5–2 min to 100% solvent B (hold), 3-mm punches were used for sulfatide analysis. C17:0, and 2–2.5 min back to 50% solvent B for reequilibration. C24:0, C16:0-day5,andC18:0-day5 sulfatides were Total injection-to-injection time was 2.5 min, and the obtained as described (8). injection volume was 10 ␮L. A triple-quadrupole tandem mass spectrometer (Xevo TQ, Waters Corp.) was used in SULFATIDE EXTRACTION AND SAMPLE PROCESSING negative- and positive-ion detection modes. Details for To extract sulfatides from DBS and DUS, 30 ␮L water MS/MS methods are provided in online Supplementary was added to a 3-mm punch in a deep (1-mL) 96-well Tables 5 and 6. An external calibration curve was ac- plate and incubated for 2 h (37 °C with orbital shaking). quired for each sample batch with C17:0 sulfatide stan- We added 300 ␮L methanol, pipetted the mixture up dard (Avanti Polar Lipids). The use of internal standard- and down approximately 10 times, and centrifuged the ization with C17:0 was not suitable because of the plate for 5 min at 3000 rpm at room temperature. A isobaric molecular mass with C16:1-OH sulfatide and portion of the supernatant (200 ␮L) was transferred to a coelution of isobaric sulfatides at UHPLC gradient con- shallow (350-␮L) 96-well plate and directly used for LC- ditions.
Load more

Recommended publications
  • Sphingolipid Metabolism Diseases ⁎ Thomas Kolter, Konrad Sandhoff
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Biochimica et Biophysica Acta 1758 (2006) 2057–2079 www.elsevier.com/locate/bbamem Review Sphingolipid metabolism diseases ⁎ Thomas Kolter, Konrad Sandhoff Kekulé-Institut für Organische Chemie und Biochemie der Universität, Gerhard-Domagk-Str. 1, D-53121 Bonn, Germany Received 23 December 2005; received in revised form 26 April 2006; accepted 23 May 2006 Available online 14 June 2006 Abstract Human diseases caused by alterations in the metabolism of sphingolipids or glycosphingolipids are mainly disorders of the degradation of these compounds. The sphingolipidoses are a group of monogenic inherited diseases caused by defects in the system of lysosomal sphingolipid degradation, with subsequent accumulation of non-degradable storage material in one or more organs. Most sphingolipidoses are associated with high mortality. Both, the ratio of substrate influx into the lysosomes and the reduced degradative capacity can be addressed by therapeutic approaches. In addition to symptomatic treatments, the current strategies for restoration of the reduced substrate degradation within the lysosome are enzyme replacement therapy (ERT), cell-mediated therapy (CMT) including bone marrow transplantation (BMT) and cell-mediated “cross correction”, gene therapy, and enzyme-enhancement therapy with chemical chaperones. The reduction of substrate influx into the lysosomes can be achieved by substrate reduction therapy. Patients suffering from the attenuated form (type 1) of Gaucher disease and from Fabry disease have been successfully treated with ERT. © 2006 Elsevier B.V. All rights reserved. Keywords: Ceramide; Lysosomal storage disease; Saposin; Sphingolipidose Contents 1. Sphingolipid structure, function and biosynthesis ..........................................2058 1.1.
    [Show full text]
  • The Neutral Glycosphingolipid Globotriaosylceramide Promotes Fusion Mediated by a CD4-Dependent CXCR4-Utilizing HIV Type 1 Envelope Glycoprotein
    Proc. Natl. Acad. Sci. USA Vol. 95, pp. 14435–14440, November 1998 Medical Sciences The neutral glycosphingolipid globotriaosylceramide promotes fusion mediated by a CD4-dependent CXCR4-utilizing HIV type 1 envelope glycoprotein ANU PURI*, PETER HUG*, KRISTINE JERNIGAN*, JOSEPH BARCHI†,HEE-YONG KIM‡,JILLON HAMILTON‡, i JOE¨LLE WIELS§,GARY J. MURRAY¶,ROSCOE O. BRADY¶, AND ROBERT BLUMENTHAL* *Section of Membrane Structure and Function, Laboratory of Experimental and Computational Biology, Division of Basic Sciences, National Cancer Institute, National Institutes of Health, Frederick, MD 21702; †Laboratory of Medicinal Chemistry, Division of Basic Sciences, National Cancer Institute and ¶Developmental and Metabolic Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892; ‡Laboratory of Membrane Biochemistry and Biophysics, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Rockville, MD 20852; and §Centre National de la Recherche Scientifique Unite´Mixte de Recherche 1598, Institut Gustave Roussy, Villejuif Cedex 94805, France Contributed by Roscoe O. Brady, September 25, 1998 ABSTRACT Previously, we showed that the addition of enabling individual HIV strains to choose between alternate human erythrocyte glycosphingolipids (GSLs) to nonhuman modes of entry into cells. CD41 or GSL-depleted human CD41 cells rendered those cells The GSL hypothesis is based on a number of observations, susceptible to HIV-1 envelope glycoprotein-mediated cell fu- including recovery of fusion of nonsusceptible cells after sion. Individual components in the GSL mixture were isolated transfer of protease- and heat-resistant components from by fractionation on a silica-gel column and incorporated into human erythrocytes (12, 13), physicochemical studies on the the membranes of CD41 cells.
    [Show full text]
  • Occurrence of Sulfatide As a Major Glycosphingolipid in WHHL Rabbit Serum Lipoproteins1
    J. Biochem. 102, 83-92 (1987) Occurrence of Sulfatide as a Major Glycosphingolipid in WHHL Rabbit Serum Lipoproteins1 Atsushi HARA and Tamotsu TAKETOMI Department of Lipid Biochemistry, Institute of Cardiovascular Disease , Shinshu University School of Medicine, Matsumoto , Nagano 390 Received for publication, February 12, 1987 Glycosphingolipids in serum and lipoproteins from Watanabe hereditable hyper li pidemic rabbit (WHHL rabbit), which is an animal model for human familial hypercholesterolemia (FH), were analyzed for the first time in this study . Chylo microns and very low density, low density, and high density lipoproteins contained sulfatide as a major glycosphingolipid (12nmol/ƒÊmol total phospholipids (PL) in chylomicrons, 19nmol/ƒÊmol PL in VLDL, 18nmol/ƒÊmol PL in LDL, and 14nmol/ƒÊ mol PL in HDL) with other minor glycosphingolipids such as glucosylceramide, galactosylceramide, GM3 ganglioside, lactosylceramide, and globotriaosylceramide. The concentration of sulfatide as a major glycosphingolipid in WHHL rabbit serum (121nmol/ml) was much higher than that in normal rabbit serum (3nmol/ml). Fatty acids of the sulfatides comprised mainly nonhydroxy fatty acids (C22, 23, and 24) and significant amounts of hydroxy fatty acids (about 10%), whereas long chain bases of the sulfatides comprised mostly (4E)-sphingenine with a significant amount of 4D-hydroxysphinganine (about 10%). Furthermore, sulfatides in the liver and small intestine from normal and WHHL rabbits (where serum lipoproteins are produced) were determined to amount to 260nmol/g liver in WHHL rabbit, 104 nmol/g liver in control rabbit, 99.6nmol/g small intestine in WHHL rabbit, and 31.2nmol/g small intestine in control rabbit. Ceramide portions of the sulfatides in the liver were mainly composed of (4E)-sphingenine and nonhydroxy fatty acids, while those in the small intestine were mainly composed of 4D-hydroxysphinganine and hydroxy fatty acids.
    [Show full text]
  • Ceramide and Related Molecules in Viral Infections
    International Journal of Molecular Sciences Review Ceramide and Related Molecules in Viral Infections Nadine Beckmann * and Katrin Anne Becker Department of Molecular Biology, University of Duisburg-Essen, 45141 Essen, Germany; [email protected] * Correspondence: [email protected]; Tel.: +49-201-723-1981 Abstract: Ceramide is a lipid messenger at the heart of sphingolipid metabolism. In concert with its metabolizing enzymes, particularly sphingomyelinases, it has key roles in regulating the physical properties of biological membranes, including the formation of membrane microdomains. Thus, ceramide and its related molecules have been attributed significant roles in nearly all steps of the viral life cycle: they may serve directly as receptors or co-receptors for viral entry, form microdomains that cluster entry receptors and/or enable them to adopt the required conformation or regulate their cell surface expression. Sphingolipids can regulate all forms of viral uptake, often through sphingomyelinase activation, and mediate endosomal escape and intracellular trafficking. Ceramide can be key for the formation of viral replication sites. Sphingomyelinases often mediate the release of new virions from infected cells. Moreover, sphingolipids can contribute to viral-induced apoptosis and morbidity in viral diseases, as well as virus immune evasion. Alpha-galactosylceramide, in particular, also plays a significant role in immune modulation in response to viral infections. This review will discuss the roles of ceramide and its related molecules in the different steps of the viral life cycle. We will also discuss how novel strategies could exploit these for therapeutic benefit. Keywords: ceramide; acid sphingomyelinase; sphingolipids; lipid-rafts; α-galactosylceramide; viral Citation: Beckmann, N.; Becker, K.A.
    [Show full text]
  • Gb3 and Lyso-Gb3 and Fabry Disease
    O H 5 OH OH C17 3 O OH OH O OH NH H C13H27 O O HAc O O N O O O O OH O OH O O OH H H HO O H CO2 H O CO2 AcHN HO HO O O H AcHN O H HO CO2 O H O C 2 O HO H O O H H AcHN O H HO O H cHN O A HO OH N E W S L E T T E R F O R G LY C O / S P H I N G O L I P I D R E S E A R C H D E C E M B E R Gb 2 0 1 9 3 and lyso -Gb 3 and Fabry Disease males. Fabry disease is a multi Fabry disease is caused by deficiency-systemic in the xalpha age of sphingolipids such as lyso -linked disorder with variable prevalence ranging from 1:3000 to 1:117000 in newborn Enzyme replacement therapy (ERT) of the disease has been available since 2001. Several studies support the clinical benefit o towards quality of life, disease progression,-Gb3 and andGb3 stabilization and-galactosidase galabiosyl of endceramide enzyme. organ (Ga2)structure Decrease in organs, and in alphafunction. tissues, and biological fluids. Thurberg 2 evaluated 48 Fabry patients on ERT and found good correlation of urinary Gb3 excretion normalized to creatine. However other studies indicated incomplete relationships between plasma and urinary Gb3 levels and disease-galactosidase manifestations. enzyme Recently, leads to the sto group 3 postulated Gb3 metabolite could play a role in Fabry pathogenesis and reposted the presence of lyso lyso-Gb3 were found in the plasma of Fabry patients and concentrations were reduced after ERT.
    [Show full text]
  • VIEW Open Access T-Cell Metabolism in Autoimmune Disease Zhen Yang1, Eric L Matteson2, Jörg J Goronzy1 and Cornelia M Weyand1*
    Yang et al. Arthritis Research & Therapy (2015) 17:29 DOI 10.1186/s13075-015-0542-4 REVIEW Open Access T-cell metabolism in autoimmune disease Zhen Yang1, Eric L Matteson2, Jörg J Goronzy1 and Cornelia M Weyand1* Abstract Cancer cells have long been known to fuel their pathogenic growth habits by sustaining a high glycolytic flux, first described almost 90 years ago as the so-called Warburg effect. Immune cells utilize a similar strategy to generate the energy carriers and metabolic intermediates they need to produce biomass and inflammatory mediators. Resting lymphocytes generate energy through oxidative phosphorylation and breakdown of fatty acids, and upon activation rapidly switch to aerobic glycolysis and low tricarboxylic acid flux. T cells in patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) have a disease-specific metabolic signature that may explain, at least in part, why they are dysfunctional. RA T cells are characterized by low adenosine triphosphate and lactate levels and increased availability of the cellular reductant NADPH. This anti-Warburg effect results from insufficient activity of the glycolytic enzyme phosphofructokinase and differentiates the metabolic status in RA T cells from those in cancer cells. Excess production of reactive oxygen species and a defect in lipid metabolism characterizes metabolic conditions in SLE T cells. Owing to increased production of the glycosphingolipids lactosylceramide, globotriaosylceramide and monosialotetrahexosylganglioside, SLE T cells change membrane raft formation and fail to phosphorylate pERK, yet hyperproliferate. Borrowing from cancer metabolomics, the metabolic modifications occurring in autoimmune disease are probably heterogeneous and context dependent. Variations of glucose, amino acid and lipid metabolism in different disease states may provide opportunities to develop biomarkers and exploit metabolic pathways as therapeutic targets.
    [Show full text]
  • The Kidney in Fabry Disease: More Than ª the Author(S) 2016 DOI: 10.1177/2326409816648169 Mere Sphingolipids Overload Iem.Sagepub.Com
    Original Article Journal of Inborn Errors of Metabolism & Screening 2016, Volume 4: 1–5 The Kidney in Fabry Disease: More Than ª The Author(s) 2016 DOI: 10.1177/2326409816648169 Mere Sphingolipids Overload iem.sagepub.com Herna´n Trimarchi, MD, PhD1 Abstract Fabry disease is a rare cause of end-stage renal disease. Renal pathology is notable for diffuse deposition of glycosphingolipid in the renal glomeruli, tubules, and vasculature. Classical patients with mutations in the a-galactosidase A gene accumulate globotriaosylceramide and become symptomatic in childhood with pain, gastrointestinal disturbances, angiokeratoma, and hypohidrosis. Classical patients experience progressive loss of renal function and hypertrophic cardiomyopathy, with severe clinical events including end-stage renal disease, stroke, arrhythmias, and premature death. The pathophysiological mechanisms by which endothelial cells, podocytes, smooth muscle cells, and tubular dysfunction occur in Fabry disease are poorly characterized and understood. This review evaluates the new evidence in pathophysiology of Fabry nephropathy, highlighting the necessity of early identification of individuals with Fabry disease. Keywords Fabry disease, globotriaosylceramide, podocyte, nitric oxide, angiotensin II Introduction of Gl3 in the endothelium and within the arterial wall, mainly in smooth muscle cells. This Gl3 and lyso-Gl3 accumulation Fabry disease is an X-linked genetic disorder of glycosphingo- in the endothelium leads to a secondary decrease in nitric lipid catabolism resulting from deficient activity of the lysoso- oxide (NO) synthesis and a trend to microthrombotic events mal enzyme a-galactosidase A (a-gal A). As a consequence, that lead to local ischemic events. In this regard, 2 primary the substrates of a-gal A, which are neutral glycosphingolipids, hypotheses have emerged to explain the pathogenesis of this mainly globotriaosylceramide (Gl3) and lyso-Gl3, accumulate vasculopathy.
    [Show full text]
  • Disorders of Sphingolipid Synthesis, Sphingolipidoses, Niemann-Pick Disease Type C and Neuronal Ceroid Lipofuscinoses
    551 38 Disorders of Sphingolipid Synthesis, Sphingolipidoses, Niemann-Pick Disease Type C and Neuronal Ceroid Lipofuscinoses Marie T. Vanier, Catherine Caillaud, Thierry Levade 38.1 Disorders of Sphingolipid Synthesis – 553 38.2 Sphingolipidoses – 556 38.3 Niemann-Pick Disease Type C – 566 38.4 Neuronal Ceroid Lipofuscinoses – 568 References – 571 J.-M. Saudubray et al. (Eds.), Inborn Metabolic Diseases, DOI 10.1007/978-3-662-49771-5_ 38 , © Springer-Verlag Berlin Heidelberg 2016 552 Chapter 38 · Disor ders of Sphingolipid Synthesis, Sphingolipidoses, Niemann-Pick Disease Type C and Neuronal Ceroid Lipofuscinoses O C 22:0 (Fatty acid) Ganglio- series a series b HN OH Sphingosine (Sphingoid base) OH βββ β βββ β Typical Ceramide (Cer) -Cer -Cer GD1a GT1b Glc ββββ βββ β Gal -Cer -Cer Globo-series GalNAc GM1a GD1b Neu5Ac βαββ -Cer Gb4 ββ β ββ β -Cer -Cer αβ β -Cer GM2 GD2 Sphingomyelin Pcholine-Cer Gb3 B4GALNT1 [SPG46] [SPG26] β β β ββ ββ CERS1-6 GBA2 -Cer -Cer ST3GAL5 -Cer -Cer So1P So Cer GM3 GD3 GlcCer - LacCer UDP-Glc UDP Gal CMP -Neu5Ac - UDP Gal PAPS Glycosphingolipids GalCer Sulfatide ββ Dihydro -Cer -Cer SO 4 Golgi Ceramide apparatus 2-OH- 2-OH-FA Acyl-CoA FA2H CERS1-6 [SPG35] CYP4F22 ω-OH- ω-OH- FA Acyl-CoA ULCFA ULCFA-CoA ULCFA GM1, GM2, GM3: monosialo- Sphinganine gangliosides Endoplasmic GD3, GD2, GD1a, GD1b: disialo-gangliosides reticulum KetoSphinganine GT1b: trisialoganglioside SPTLC1/2 [HSAN1] N-acetyl-neuraminic acid: sialic acid found in normal human cells Palmitoyl-CoA Deoxy-sphinganine + Serine +Ala or Gly Deoxymethylsphinganine 38 . Fig. 38.1 Schematic representation of the structure of the main sphingolipids , and their biosynthetic pathways.
    [Show full text]
  • Mechanism of Secondary Ganglioside and Lipid Accumulation in Lysosomal Disease
    International Journal of Molecular Sciences Review Mechanism of Secondary Ganglioside and Lipid Accumulation in Lysosomal Disease Bernadette Breiden and Konrad Sandhoff * Membrane Biology and Lipid Biochemistry Unit, LIMES Institute, University of Bonn, 53121 Bonn, Germany; [email protected] * Correspondence: sandhoff@uni-bonn.de; Tel.: +49-228-73-5346 Received: 5 March 2020; Accepted: 4 April 2020; Published: 7 April 2020 Abstract: Gangliosidoses are caused by monogenic defects of a specific hydrolase or an ancillary sphingolipid activator protein essential for a specific step in the catabolism of gangliosides. Such defects in lysosomal function cause a primary accumulation of multiple undegradable gangliosides and glycosphingolipids. In reality, however, predominantly small gangliosides also accumulate in many lysosomal diseases as secondary storage material without any known defect in their catabolic pathway. In recent reconstitution experiments, we identified primary storage materials like sphingomyelin, cholesterol, lysosphingolipids, and chondroitin sulfate as strong inhibitors of sphingolipid activator proteins (like GM2 activator protein, saposin A and B), essential for the catabolism of many gangliosides and glycosphingolipids, as well as inhibitors of specific catabolic steps in lysosomal ganglioside catabolism and cholesterol turnover. In particular, they trigger a secondary accumulation of ganglioside GM2, glucosylceramide and cholesterol in Niemann–Pick disease type A and B, and of GM2 and glucosylceramide in Niemann–Pick disease
    [Show full text]
  • Novel Intrinsic and Extrinsic Approaches to Selectively Regulate
    Novel Intrinsic and Extrinsic Approaches to Selectively Regulate Glycosphingolipid Metabolism by Mustafa Ali Kamani A thesis submitted in conformity with the requirements for the degree of Doctor of Philosophy Graduate Department of Biochemistry University of Toronto © Copyright by Mustafa Ali Kamani 2013. Novel Intrinsic and Extrinsic Approaches to Selectively Regulate Glycosphingolipid Metabolism. Doctor of Philosophy, 2013. Mustafa Ali Kamani Department of Biochemistry University of Toronto Abstract Glycosphingolipid (GSL) metabolism is a complex process involving proteins and enzymes at distinct locations within the cell. Mammalian GSLs are typically based on glucose or galactose, forming glucosylceramide (GlcCer) and galactosylceramide (GalCer). Most GSLs are derived from GlcCer, which is synthesized on the cytosolic leaflet of the Golgi, while all subsequent GSLs are synthesized on the lumenal side. We have utilized both pharamacological and genetic manipulation approaches to selectively regulate GSL metabolism and better understand its mechanistic details. We have developed analogues of GlcCer and GalCer by substituting the fatty acid moiety with an adamanatane frame. The resulting adamantylGSLs are more water- soluble than their natural counterparts. These analogues selectively interfere with GSL metabolism at particular points within the metabolic pathway. At 40 µM, adaGlcCer prevents synthesis of all GSLs downstream of GlcCer, while also elevating GlcCer levels, by inhibiting lactosylceramide (LacCer) synthase and glucocerebrosidase, respectively. AdaGalCer specifically reduces synthesis of globotriaosylceramide (Gb3) and downstream globo-series GSLs. AdaGalCer also increases Gaucher disease N370S glucocerebrosidase expression, lysosomal localization and activity. AdaGSLs, therefore, have potential as novel therapeutic ii agents in diseases characterized by GSL anomalies and as tools to study the effects of GSL modulation.
    [Show full text]
  • Review Article Ganglioside Biochemistry
    International Scholarly Research Network ISRN Biochemistry Volume 2012, Article ID 506160, 36 pages doi:10.5402/2012/506160 Review Article Ganglioside Biochemistry Thomas Kolter Program Unit Membrane Biology & Lipid Biochemistry, LiMES, University of Bonn, Gerhard-Domagk Straße 1, 53121 Bonn, Germany Correspondence should be addressed to Thomas Kolter, [email protected] Received 18 September 2012; Accepted 9 October 2012 Academic Editors: H. Itoh and B. Penke Copyright © 2012 Thomas Kolter. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Gangliosides are sialic acid-containing glycosphingolipids. They occur especially on the cellular surfaces of neuronal cells, where they form a complex pattern, but are also found in many other cell types. The paper provides a general overview on their structures, occurrence, and metabolism. Key functional, biochemical, and pathobiochemical aspects are summarized. 1. Introduction 2. Structure and Nomenclature Together with glycoproteins and glycosaminoglycans, gly- In their structures, gangliosides combine a glycan and a lipid cosphingolipids (GSLs) contribute to the glycocalyx that portion and contribute to both, the cellular lipidome and covers eukaryotic cell surfaces. Gangliosides are sialic acid- the glycome/sialome [15]. A great variety of carbohydrate containing glycosphingolipids and provide a significant part sequences are found within the GSLs [16], including the of cell surface glycans on neuronal cells. GSLs are lipids gangliosides [17]. Although carbohydrate residues of dif- that contain a sphingoid base and one or more sugar ferent structure, linkage, and anomeric configuration occur residues [1]. Sialic acids (Figure 1) are nine-carbon sugars in GSLs, only a limited number of the so-called series biosynthetically formed from N-acetylmannosamine and with characteristic carbohydrate sequences are found within phosphoenolpyruvate [2, 3].
    [Show full text]
  • Low Frequency of Fabry Disease in Patients with Common Heart Disease
    ORIGINAL RESEARCH ARTICLE Low frequency of Fabry disease in patients with common heart disease Raphael Schiffmann, MD, MHSc1, Caren Swift, RN1, Nathan McNeill, PhD1, Elfrida R. Benjamin, PhD2, Jeffrey P. Castelli, PhD2, Jay Barth, MD, PhD2, Lawrence Sweetman, PhD1, Xuan Wang, PhD1 and Xiaoyang Wu, PhD2 Purpose: To test the hypothesis that undiagnosed patients with (n = 7); IVS6-22 C > T, IVS4-16 A > G, IVS2+990C > A, 5′UTR-10 Fabry disease exist among patients affected by common heart C > T(n = 4), IVS1-581 C > T, IVS1-1238 G > A, 5′UTR-30 G > A, disease. IVS2+590C > T, IVS0-12 G > A, IVS4+68A > G, IVS0-10 C > T, – Methods: Globotriaosylceramide in random whole urine using IVS2-81 77delCAGCC, IVS2-77delC. Although the pathogenicity of tandem mass spectroscopy, α-galactosidase A activity in dried several of these missense mutations and complex intronic haplotypes blood spots, and next-generation sequencing of pooled or has been controversial, none of the patients screened in this study individual genomic DNA samples supplemented by Sanger were diagnosed definitively with Fabry disease. sequencing. Conclusion: This population of patients with common heart disease Results: We tested 2,256 consecutive patients: 852 women (median did not contain a substantial number of patients with undiagnosed – – Fabry disease. GLA gene sequencing is superior to urinary age 65 years (19 95)) and 1,404 men (median age 65 years (21 92)). α The primary diagnoses were coronary artery disease (n = 994), globotriaosylceramide or -galactosidase A activity in the screening arrhythmia (n = 607), cardiomyopathy (n = 138), and valvular for Fabry disease.
    [Show full text]